You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

LIPITOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lipitor patents expire, and when can generic versions of Lipitor launch?

Lipitor is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lipitor

A generic version of LIPITOR was approved as atorvastatin calcium by SUN PHARM INDS LTD on November 30th, 2011.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LIPITOR?
  • What are the global sales for LIPITOR?
  • What is Average Wholesale Price for LIPITOR?
Drug patent expirations by year for LIPITOR
Drug Prices for LIPITOR

See drug prices for LIPITOR

Drug Sales Revenue Trends for LIPITOR

See drug sales revenues for LIPITOR

Recent Clinical Trials for LIPITOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NYU Langone HealthPhase 4
Gannex Pharma Co., Ltd.Phase 1
Montefiore Medical CenterN/A

See all LIPITOR clinical trials

Pharmacology for LIPITOR

US Patents and Regulatory Information for LIPITOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-001 Dec 17, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-004 Apr 7, 2000 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-002 Dec 17, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LIPITOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-002 Dec 17, 1996 ⤷  Sign Up ⤷  Sign Up
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-003 Dec 17, 1996 ⤷  Sign Up ⤷  Sign Up
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-001 Dec 17, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LIPITOR

See the table below for patents covering LIPITOR around the world.

Country Patent Number Title Estimated Expiration
Japan 2003201236 PHARMACEUTICAL COMPOSITION FOR TREATING HYPERCHOLESTEROLEMIA ⤷  Sign Up
Norway 932075 ⤷  Sign Up
Argentina 003459 FORMA III CRISTALINA DE ATORVASTATINA Y SUS HIDRATOS Y COMPOSICIONES FARMACEUTICAS CON LA MISMA. ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LIPITOR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1003503 C01003503/01 Switzerland ⤷  Sign Up PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006
0247633 9790036 Sweden ⤷  Sign Up PRODUCT NAME: ATORVASTIN OCH FARMACEUTISKT GODTAGBARA SALTER DäRAV; NAT. REGISTRATION NO/DATE: 13415 19970417; FIRST REG.: GB PL00018/0240 19961107
0720599 92545 Luxembourg ⤷  Sign Up PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.